C. R. Bard
Clinical trials sponsored by C. R. Bard, explained in plain language.
Now part of
Becton, Dickinson and Company
BDX
NYSE
Medical device company, acquired by BD, known for vascular and urology products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a less invasive catheter replace the tube in intensive care? Results expected Oct 2026 (estimated)
- New balloon could help dialysis patients avoid repeat procedures Results expected Apr 2027 (estimated)
- New device aims to simplify dialysis access for kidney patients Results expected Jun 2027 (estimated)